Newsletter
Glenmark Specialty S.A. (GSSA) has entered into an exclusive agreement with China-based Jiangsu Hansoh Pharmaceutical Group.
Glenmark Specialty SA, the specialised arm of Glenmark Pharma, focuses on developing and marketing medicines, particularly in oncology and other complex therapies, for markets outside India.
Jiangsu Hansoh, on the other hand, is a major pharmaceutical player engaged in the research, development, manufacturing, and sale of medicines, with a strong focus on oncology, central nervous system, and anti-infective treatments.
So, what’s the deal about: the agreement centres on Aumolertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor used to treat non-small cell lung cancer.
In simpler terms, it is a new-generation cancer drug designed to block the signals that help cancer cells grow and spread.
Under the agreement, Glenmark also receives exclusive rights to develop and commercialise the medicine across a wide set of regions, including the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, and select Caribbean countries.
Why it matters: non-small cell lung cancer makes up nearly 80-85% of all lung cancer cases worldwide, making it the biggest battleground in cancer treatment.
Because lung cancer remains one of the most common, and deadliest cancers globally & drugmakers are racing to develop more advanced, targeted therapies that work better and improve patient outcomes.
